Comparison of Candesartan vs Amlodipine Comparison of ...

More documents

Recommendations

Info

Medications at at Randomization Randomization Candesartan < 8mg/day ACEis > 8mg/day CCalcium l i channel h l blockers bl k Beta blockers Di Diuretics ti Statins Nit Nitrates t Aspirin Candesartan Standard (n=1024 n=1024) (n=1025 n=1025) 771 (75%) 253 (25%) not allowed not allowed 723 (71%) 457 (45%) 574 (56%) 464 (45%) 103 (10%) 459 (45%) 503 (49%) 948 (93%) 506 (49%) 82 (8%) 447 (44%) 526 (51%) 935 (91%)
Blood Pressure Pressure Changes (mmHg) 180 Candesartan Standard 160 SBP Mean±SD 140 120 100 80 60 DBP P=0.379 P=0.194 40 Baseline 6 12 24 36 48 60(months) PP-value: l ttrend d profile fil ttest t bby mixed-model i d d l
Page 1 and 2:
Comparison of Candesartan vs Amlodi
Page 3 and 4: 30 20 10 0 ‐10 ‐20 ‐30 ‐40
Page 5 and 6: LIFE Incidence of Diabetes Mellitus
Page 7 and 8: m2 Change in LVVMI (g/m ) LIFE Echo
Page 9 and 10: ARBs for New-onset Atrial Fibrillat
Page 11 and 12: % New-onset AF with ARB Preventive
Page 14 and 15: Beyond BP effect of ARBs • Hi Hig
Page 16 and 17: CASE CASE-J CASE J CCandesartan d t
Page 18 and 19: Outline of the study Objectives : A
Page 20 and 21: Dosage Schedule Schedule 1 month BP
Page 22 and 23: Endpoints Primary imary Endpoints A
Page 24 and 25: Patient Characteristics Ttl Total n
Page 26 and 27: Antihypertensive Antihypertensive D
Page 28 and 29: Comparison of Cardiovascular Cardio
Page 30 and 31: Time Time-specific Time Time-specif
Page 32 and 33: Renal Renal Events Events per 1000
Page 34 and 35: CASE-J vs. VALUE
Page 36 and 37: Primary endpoint VALUE (Valsartan)
Page 38 and 39: BP reduction during studies mmHg SB
Page 40 and 41: All-cause mortality (CASE-J Primary
Page 42 and 43: New New-onset New New-onset onset D
Page 44 and 45: Conclusions Candesartan and Amlodip
Page 46 and 47: Background ACE ACE-inhibitors i hib
Page 48 and 49: Eligibility Inclusion criteria : An
Page 50 and 51: Endpoint Primary Endpoint Major Adv
Page 52 and 53: Patient Characteristics (1) Candesa
Page 56 and 57: Primary Primary Endpoint Cumulative
Page 58 and 59: Candesartan vs vs Standard Standard
Page 60 and 61: Subgroup Subgroup analysis analysis
Page 62 and 63: Summary IIn comparison i with i h s
Page 64: Conclusions Candesartan and Amlodip
Page 68 and 69: % Isolated systolic hypertension 0
Page 70: Predictors of new-onset atrial fibr
show all

Comparison of Candesartan vs Amlodipine Comparison of ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?